OVERVIEW

An Overview of GLP-1 RAs: What Every Pharmacist Should Know (Part 1) is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians.

Published Date: December 13, 2019
Expiration Date: December 31, 2020

Credits: 1.25 hours (0.125 ceu)

Goal:
Type 2 diabetes mellitus (T2DM) accounts for approximately 90% to 95% of diabetes cases and is challenging to manage, with contributing pathophysiologic abnormalities ranging from predominant insulin resistance with relative insulin deficiency to predominant insulin secretory defect with insulin resistance. The leading cause of death in people with T2DM is cardiovascular disease (CVD), and patients with T2DM are at an increased risk of multiple cardiovascular comorbidities, such as heart failure and stroke. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a class of glucose-lowering medications capable of reducing cardiovascular risk while also helping patients achieve individualized glycemic goals; however, many clinicians remain unaware of both emerging cardiovascular and renal risk reduction data with these agents and recommendations for appropriate use of these agents in clinical practice.

Educational Objectives:
Upon completion of this program, participants should be better able to:
• Review the physiologic action, efficacy, safety, advantages, and disadvantages of the GLP-1 receptor agonist medication class.
• Recognize individual agents within the GLP-1 RA class and understand medication-specific attributes that are important to consider when selecting a GLP-1 RA for use in a specific patient.
• Identify GLP-1 RAs in late stage development with the potential to impact patient care in the future.

Additional details will be posted as soon as information is available.